Abstract:Background: Clonidine is a frequently prescribed long-term antihypertensive medication in hemodialysis (HD) patients in the USA, but its safety and efficacy has not been clearly established in the HD population. Objective: To evaluate, we conducted a systematic review and meta-analysis on the safety and efficacy of clonidine in HD patients. Methods: Keyword search of "clonidine" and "dialysis" was conducted through April 2021 in PubMed, Cochrane Library, Web of Science, Scopus, and ClinicalTrials.gov databases. Inclusion criteria were as follows - study design: randomized controlled trials, cohort studies, prospective studies, retrospective studies, or case series; subjects: adult HD patients; main outcome: blood pressure (BP) and safety; language: English; and article type: peer-reviewed publications. Studies that examined the effects of clonidine in populations other than adult HD patients were excluded. Meta-analysis was performed on BP reduction outcomes. Results: Eight studies met the inclusion criteria for the systematic review, including prospective pre-post studies (2), double-blind controlled trial (1), single-blinded placebo-controlled trial (1), crossover open-label clinical trial (1), retrospective analysis (1), and case report series (2). Three studies included in the meta-analysis ranged from 2 to 12 weeks duration, with a collective sample size of 24 (ages 12-77 years). Risk of bias, assessed using the ROBINS-1 tool, was high for all included studies. Significant adverse effects reported included hypotension, light-headedness, drowsiness, dry mouth, rebound hypertension, and contact dermatitis from patch application. Short-term clonidine use was associated with significant improvement in systolic BP (pooled effect: -12.985 mm Hg, 95% CI [-7.878, -18.092], p < 0.001), while changes in diastolic BP were not statistically significant (-11.119 mm Hg, 95% CI [-22.725, 0.487], p = 0.060). No data currently support the long-term efficacy of clonidine in HD patients. This study was unfunded and was developed using PRISMA guidelines and registered on PROSPERO (CRD42018112042). Conclusions: There is no evidence supporting the long-term use of clonidine in the HD population and a significant side-effect profile. There is low-quality evidence demonstrating the efficacy of clonidine in lowering BP in HD patients in short-term use, but significant safety concerns remain. Fluid removal strategies and other antihypertensives should be used over clonidine for long-term BP control in the HD population.

Treatment of chronic hypertension with intravenous enalaprilat and transdermal clonidine

Transdermal clonidine as an adjunct to enalapril: an evaluation of efficacy and patient compliance

Transdermal clonidine as an adjunct to nifedipine-GITS therapy in patients with mild-to-moderate hypertension

Long-term treatment with transdermal clonidine in mild hypertension

A double-blind comparison of transdermal clonidine and oral captopril in essential hypertension

Strategy for the treatment of noncompliant hypertensive hemodialysis patients

The USA experience with the clonidine transdermal therapeutic system

Therapeutic adherence in the elderly: transdermal clonidine compared to oral verapamil for hypertension

Clonidine for the treatment of supine hypertension and pressure natriuresis in autonomic failure

Transdermal clonidine in mild hypertension. A randomized, double-blind, placebo-controlled trial

New indices in the evaluation of clonidine transdermal therapy of hypertension

Assessment of haemodynamic response to tracheal intubation and prone positioning following clonidine and enalaprilat in lumbar spine surgeries: A double blind randomised controlled trial

Transdermal clonidine therapy and blood pressure nocturnal fall in mild hypertensive male subjects

Clinical experience with transdermal clonidine in African-American and Hispanic-American patients with hypertension: evaluation from a 12-week prospective, open-label clinical trial in community-based clinics

Antihypertensive effects of a new transdermal delivery system for clonidine in genetic and experimental hypertensive rats

Management of patients with uncontrolled arterial hypertension – the role of electronic compliance monitoring, 24-h ambulatory blood pressure monitoring and Candesartan/HCT

One year efficacy and tolerability of clonidine administered by the transdermal route in patients with mild to moderate essential hypertension--a multicentre open label study. The Antihypertensive Patch Italian Study (APIS) Investigators

The Safety and Efficacy of Clonidine in Hemodialysis Patients: A Systematic Review and Meta-Analysis

Effects of transdermal clonidine in young and elderly patients with mild hypertension: evaluation by three noninvasive methods of blood pressure measurement

Transdermal clonidine compared with hydrochlorothiazide as monotherapy in elderly hypertensive males

Effect of Treatment of Borderline Hypertension on Microalbuminuria in Non-Insulin-dependent Diabetes Mellitus.